Eslicarbazepine is a new dibenzazepine antiepileptic agent. It is a high affinity antagonist of
the voltage-gated sodium channel. It is closely related to both carbamazepine and …

Eslicarbazepine acetate (ESL) is a once-daily antiseizure medication (ASM) that is approved
in Europe and the USA for the treatment of focal-onset seizures. The Euro-Esli study, which …

Objective We assessed the efficacy and safety of once‐daily eslicarbazepine acetate in
comparison with twice‐daily (BID) controlled‐release carbamazepine (carbamazepine‐CR) …

This study investigates the pharmacokinetics of eslicarbazepine acetate (ESL), a new
voltage‐gated sodium channel blocker, in epileptic children aged 2 to 7 years (n= 11) and 7 …

Objective To assess seizure control and tolerability of eslicarbazepine acetate (ESL) as
adjunctive therapy to one baseline antiepileptic drug (AED), in adults with partial‐onset …

Eslicarbazepine acetate is a novel voltage-gated sodium channel blocker in development
for the treatment of epilepsy, bipolar disorder and neuropathic pain. The objective of this …

The gene polymorphisms of ABCB1, EPHX1, and SCN1A were found to influence
carbamazepine (CBZ) metabolism and resistance in epilepsy patients, but the relevance …

OBJECTIVE: Investigate the safety of eslicarbazepine acetate (ESL) as adjunctive therapy
for partial-onset seizures (POS) with/without concomitant carbamazepine (CBZ) …

Efficacy and Safety of Eslicarbazepine Acetate as Adjunctive Treatment in Adults with
Refractory Partial-Onset Seizures: A Randomized, Double-Blind, Placebo-Controlled …

Purpose We report on the safety and efficacy of eslicarbazepine acetate (ESL) in routine
clinical practice. Method Retrospective multicentre audit of outcomes following ESL …